Abstract
During the investigation of a neonate with NADH-methemoglobin (NADH-MetHb) reductase deficiency (baseline MetHb, 28%), we noticed disparate readings between the ward-based, whole-blood HemoCue B-Glucose Analyzer (HemoCue AB) and the main laboratory plasma glucose method (glucose oxidase) performed on a Synchron CX7 Delta analyzer (Beckman Coulter). The HemoCue results suggested profound hypoglycemia, which was out of keeping with the clinical status of the patient, whereas the Synchron CX7 Delta results were consistently within the pediatric reference interval. These findings were contrary to the previously documented overestimation of the HemoCue analyzer at low glucose concentrations (1)(2)(3). Because the HemoCue analyzer (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11) uses a mutarose–glucose dehydrogenase enzyme system to produce a colored formazan, which is then quantified photometrically, the possibility of spectral interference by MetHb with the HemoCue analyzer was raised and investigated …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
